David Saxon, an analyst from Needham, reiterated the Buy rating on RxSight. The associated price target was raised to $12.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
David Saxon has given his Buy rating due to a combination of factors including RxSight’s impressive third-quarter revenue performance, which exceeded market expectations. The company’s management has also raised the midpoint of its financial guidance, indicating confidence in future growth.
Additionally, RxSight is adopting a more strategic approach to its LDD placements, focusing on increasing LAL volumes through various engagement initiatives. The company is also targeting consistent quarterly growth in 2026, and its gross margin is expected to remain robust, staying in the high-70% range. These positive indicators collectively support the Buy rating.